- Sangamo BioSciences (NASDAQ:SGMO +6.1%) Q2 results: Total Revenues: $10.4M (+49.8%), Collaboration Agreements: $9.7M (+57.9%); Operating Expenses: $17.4M (+40.6%); Net Loss: ($7.0M) (-28.1%); Quick Assets: $236.7M (+79.6%).
- 2014 Guidance: Revenues: $45M - 50M; Operating expenses: $65M - 70M; Quick Assets: at least $225M by year end.
More on Sangamo Q2 results
Recommended For You
About SGMO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SGMO | - | - |
Sangamo Therapeutics, Inc. |